Spectrum of radiopharmaceuticals in nuclear oncology

Current Cancer Drug Targets

Volumn 6, Issue 3, 2006, Pages 181-196

  Denoyer, Delphine ^a,b   Perek, Nathalie ^a   Le Jeune, Nathalie ^a   Dubois, Francis ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Angiogenesis; Apoptosis; Cell proliferation; Hypoxia; Multidrug resistance; PET; SPECT; Tumor imaging

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; SUCCIMER TC 99M; THALLIUM 201; TRACER; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; AMINO ACID TRANSPORT; ANGIOGENESIS; APOPTOSIS; CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CELL HYPOXIA; CELL PROLIFERATION; DNA SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVITY; EVALUATION; GLUCOSE METABOLISM; HUMAN; IN VIVO STUDY; LIPID METABOLISM; LONG TERM CARE; MULTIDRUG RESISTANCE; NON INVASIVE PROCEDURE; ONCOLOGY; PHOSPHATE TRANSPORT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANOXIA; APOPTOSIS; CELL PROLIFERATION; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOPHARMACEUTICALS;

EID: 33646773192     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906776842984     Document Type: Review

References (155)

1. Gallagher, B. M.; Fowler, J. S.; Gutterson, N. I.; MacGregor, R. R.; Wan, C. N.; Wolf, A. P. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J. Nucl. Med. 1978, 19, 1154-1161.
2. Van de Wiele, C.; Lahorte, C.; Oyen, W.; Boerman, O.; Goethals, I.; Slegers, G.; Dierckx, R. A. Nuclear medicine imaging to predict response to radiotherapy: a review. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55, 5-15.
3. Smith, T. A. Mammalian hexokinases and their abnormal expression in cancer. Br. J. Biomed. Sci. 2000, 57, 170-178.
4. Spaepen, K.; Stroobants, S.; Dupont, P.; Bormans, G.; Balzarini, J.; Verhoef, G.; Mortelmans, L.; Vandenberghe, P.; De Wolf-Peeters, C. [(18)F]FDG PET monitoring of tumor response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumor cell fraction? Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 682-688. [Epub 2003 Feb 25]
5. Vesselle, H.; Schmidt, R. A.; Pugsley, J. M.; Li, M.; Kohlmyer, S. G.; Vallires, E.; Wood, D. E. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin. Cancer Res. 2000, 6, 3837-3844.
6. Smith, I. C.; Welch, A. E.; Hutcheon, A. W.; Miller, I. D.; Payne, S.; Chilcott, F.; Waikar, S.; Whitaker, T.; Ah-See, A. K.; Eremin, O.; Heys, S. D.; Gilbert, F. J.; Sharp, P. F. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol. 2000, 18, 1676-1688.
7. Stroobants, S.; Goeminne, J.; Seegers, M.; Dimitrijevic, S.; Dupont, P.; Nuyts, J.; Martens, M.; van den Borne, B.; Cole, P.; Sciot, R.; Dumez, H.; Silberman, S.; Mortelmans, L.; van Oosterom, A. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer 2003, 39, 2012-2020.
8. Boren, J.; Cascante, M.; Marin, S.; Comin-Anduix, B.; Centelles, J. J.; Lim, S.; Bassilian, S.; Ahmed, S.; Lee, W. N.; Boros, L. G. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol. Chem. 2001, 276, 37747-37753. [Epub 2001 Aug 6]
9. Wieder, H. A.; Brucher, B. L.; Zimmermann, F.; Becker, K.; Lordick, F.; Beer, A.; Schwaiger, M.; Fink, U.; Siewert, J. R.; Stein, H. J.; Weber, W. A. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J. Clin. Oncol. 2004, 22, 900-908.
10. Yoshioka, M.; Sato, T.; Furuya, T.; Shibata, S.; Andoh, H.; Asanuma, Y.; Hatazawa, J.; Shimosegawa, E.; Koyama, K.; Yamamoto, Y. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J. Gastroenterol. 2004, 39, 50-55.
11. Yao, M.; Graham, M. M.; Smith, R. B.; Dornfeld, K. J.; Skwarchuk, M.; Hoffman, H. T.; Funk, G. F.; Graham, S. M.; Menda, Y.; Buatti, J. M. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 1410-1418.
12. Swisher, S. G.; Erasmus, J.; Maish, M.; Correa, A. M.; Macapinlac, H.; Ajani, J. A.; Cox, J. D.; Komaki, R. R.; Hong, D.; Lee, H. K.; Putnam, J. B., Jr.; Rice, D. C.; Smythe, W. R.; Thai, L.; Vaporciyan, A. A.; Walsh, G. L.; Wu, T. T.; Roth, J. A. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004, 101, 1776-1785.
13. Buck, A. K.; Halter, G.; Schirrmeister, H.; Kotzerke, J.; Wurziger, I.; Glatting, G.; Mattfeldt, T.; Neumaier, B.; Reske, S. N.; Hetzel, M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med. 2003, 44, 1426-1431.
14. Kubota, R.; Kubota, K.; Yamada, S.; Tada, M.; Ido, T.; Tamahashi, N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J. Nucl. Med. 1994, 35, 104-112.
15. Biersack, H. J.; Bender, H.; Palmedo, H. FDG-PET in monitoring therapy of breast cancer. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, S112-S117. [Epub 2004 Apr 27]
16. Dehdashti, F.; Flanagan, F. L.; Mortimer, J. E.; Katzenellenbogen, J. A.; Welch, M. J.; Siegel, B. A. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur. J. Nucl. Med. 1999, 26, 51-56.
17. Findlay, M.; Young, H.; Cunningham, D.; Iveson, A.; Cronin, B.; Hickish, T.; Pratt, B.; Husband, J.; Flower, M.; Ott, R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J. Clin. Oncol. 1996, 14, 700-708.
18. Isselbacher, K. J. Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture. Proc. Natl. Acad. Sci. USA 1972, 69, 585-589.
19. Couturier, O.; Luxen, A.; Chatal, J. F.; Vuillez, J. P.; Rigo, P.; Hustinx, R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1182-1206. [Epub 2004 Jul 6]
20. Kubota, K.; Matsuzawa, T.; Fujiwara, T.; Sato, T.; Tada, M.; Ido, T.; Ishiwata, K. Differential diagnosis of AH109A tumor and inflammation by radioscintigraphy with L-[methyl-11C]methionine. Jpn. J. Cancer Res. 1989, 80, 778-782.
21. Kubota, R.; Yamada, S.; Kubota, K.; Ishiwata, K.; Tamahashi, N.; Ido, T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 1992, 33, 1972-1980.
22. Kubota, R.; Kubota, K.; Yamada, S.; Tada, M.; Takahashi, T.; Iwata, R.; Tamahashi, N. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J. Nucl. Med. 1995, 36, 484-492.
23. Herholz, K.; Kracht, L. W.; Heiss, W. D. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J. Neuroimaging 2003, 13, 269-271.
24. Van Laere, K.; Ceyssens, S.; Van Calenbergh, F.; de Groot, T.; Menten, J.; Flamen, P.; Bormans, G.; Mortelmans, L. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 39-51. [Epub 2004 Aug 10]
25. Macapinlac, H. A.; Humm, J. L.; Akhurst, T.; Osman, I.; Pentlow, K.; Shangde, C.; Yeung, H. W.; Squire, O.; Finn, R. D.; Scher, H. I.; Larson, S. M. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clin. Positron Imaging 1999, 2, 173-181.
26. Jackowski, S. Coordination of membrane phospholipid synthesis with the cell cycle. J. Biol. Chem. 1994, 269, 3858-3867.
27. Terce, F.; Brun, H.; Vance, D. E. Requirement of phosphatidylcholine for normal progression through the cell cycle in C3H/10T1/2 fibroblasts. J. Lipid Res. 1994, 35, 2130-2142.
28. Hara, T.; Kosaka, N.; Shinoura, N.; Kondo, T. PET imaging of brain tumor with [methyl-11C]choline. J. Nucl. Med. 1997, 38, 842-847.
29. Hara, T.; Kosaka, N.; Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 1998, 39, 990-995.
30. Zheng, Q. H.; Gardner, T. A.; Raikwar, S.; Kao, C.; Stone, K. L.; Martinez, T. D.; Mock, B. H.; Fei, X.; Wang, J. Q.; Hutchins, G. D. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg. Med. Chem. 2004, 12, 2887-2893.
31. de Jong, I. J.; Pruim, J.; Elsinga, P. H.; Vaalburg, W.; Mensink, H. J. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol. 2003, 44, 32-38; discussion 38-39.
32. Picchio, M.; Messa, C.; Landoni, C.; Gianolli, L.; Sironi, S.; Brioschi, M.; Matarrese, M.; Matei, D. V.; De Cobelli, F.; Del Maschio, A.; Rocco, F.; Rigatti, P.; Fazio, F. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J. Urol. 2003, 169, 1337-1340.
33. Kwee, S. A.; Coel, M. N.; Lim, J.; Ko, J. P. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J. Urol. 2005, 173, 252-255.
34. Price, D. T.; Coleman, R. E.; Liao, R. P.; Robertson, C. N.; Polascik, T. J.; DeGrado, T. R. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J. Urol. 2002, 168, 273-280.
35. Wyss, M. T.; Weber, B.; Honer, M.; Spath, N.; Ametamey, S. M.; Westera, G.; Bode, B.; Kaim, A. H.; Buck, A. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 312-316. [Epub 2003 Nov 20]
36. Yoshimoto, M.; Waki, A.; Obata, A.; Furukawa, T.; Yonekura, Y.; Fujibayashi, Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl. Med. Biol. 2004, 31, 859-865.
37. Nakagami, K.; Uchida, T.; Ohwada, S.; Koibuchi, Y.; Suda, Y.; Sekine, T.; Morishita, Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res. 1999, 90, 419-424.
38. Finney, R. E.; Nudelman, E.; White, T.; Bursten, S.; Klein, P.; Leer, L. L.; Wang, N.; Waggoner, D.; Singer, J. W.; Lewis, R. A. Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000, 60, 5204-5213.
39. Hernandez-Alcoceba, R.; Fernandez, F.; Lacal, J. C. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999, 59, 3112-3118.
40. Yoshimoto, M.; Waki, A.; Yonekura, Y.; Sadato, N.; Murata, T.; Omata, N.; Takahashi, N.; Welch, M. J.; Fujibayashi, Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol. 2001, 28, 117-122.
41. Kotzerke, J.; Volkmer, B. G.; Glatting, G.; van den Hoff, J.; Gschwend, J. E.; Messer, P.; Reske, S. N.; Neumaier, B. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003, 42, 25-30.
42. Schwartz, J. L.; Tamura, Y.; Jordan, R.; Grierson, J. R.; Krohn, K. A. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J. Nucl. Med. 2003, 44, 2027-2032.
43. Rasey, J. S.; Grierson, J. R.; Wiens, L. W.; Kolb, P. D.; Schwartz, J. L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med. 2002, 43, 1210-1217.
44. Vesselle, H.; Grierson, J.; Muzi, M.; Pugsley, J. M.; Schmidt, R. A.; Rabinowitz, P.; Peterson, L. M.; Vallieres, E.; Wood, D. E. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin. Cancer Res. 2002, 8, 3315-3323.
45. Buck, A. K.; Schirrmeister, H.; Hetzel, M.; Von Der Heide, M.; Halter, G.; Glatting, G.; Mattfeldt, T.; Liewald, F.; Reske, S. N.; Neumaier, B. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002, 62, 3331-3334.
46. Shields, A. F.; Grierson, J. R.; Muzik, O.; Stayanoff, J. C.; Lawhorn-Crews, J. M.; Obradovich, J. E.; Mangner, T. J. Kinetics of 3′-deoxy-3′-[F-18]fluorothymidine uptake and retention in dogs. Mol. Imaging Biol. 2002, 4, 83-89.
47. Dohmen, B. M.; Shields, A. F.; Dittmann, H.; Fersis, N.; Eschmann, S. M.; Philip, P.; Reimold, M.; Machulla, H. J.; Bares, R. Use of [18F]FLT for breast cancer imaging. J. Nucl. Med. 2001, 42, 107.
48. Sugiyama, M.; Sakahara, H.; Sato, K.; Harada, N.; Fukumoto, D.; Kakiuchi, T.; Hirano, T.; Kohno, E.; Tsukada, H. Evaluation of 3′-deoxy-3′- 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J. Nucl. Med. 2004, 45, 1754-1758.
49. Barthel, H.; Cleij, M. C.; Collingridge, D. R.; Hutchinson, O. C.; Osman, S.; He, Q.; Luthra, S. K.; Brady, F.; Price, P. M.; Aboagye, E. O. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003, 63, 3791-3798.
50. Dittmann, H.; Dohmen, B. M.; Kehlbach, R.; Bartusek, G.; Pritzkow, M.; Sarbia, M.; Bares, R. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1462-1469. [Epub 2002 Sep 6].
51. Oyama, N.; Ponde, D. E.; Dence, C.; Kim, J.; Tai, Y. C.; Welch, M. J. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J. Nucl. Med. 2004, 45, 519-525.
52. Oyama, N.; Kim, J.; Jones, L. A.; Mercer, N. M.; Engelbach, J. A.; Sharp, T. L.; Welch, M. J. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl. Med. Biol. 2002, 29, 783-790.
53. Effert, P. J.; Bares, R.; Handt, S.; Wolff, J. M.; Bull, U.; Jakse, G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol. 1996, 155, 994-998.
54. Britten, J. S.; Blank, M. Thallium activation of the (Na+ - K+)-activated ATPase of rabbit kidney. Biochim. Biophys. Acta 1968, 159, 160-166.
55. Sato, T.; Indo, H.; Kawabata, Y.; Kobayashi, T.; Suenaga, S.; Iwashita, Y.; Nitta, T.; Sugihara, K.; Majima, H. J. Thallium-201 chloride (Tl-201) accumulation and Na+/K+-ATPase expression in tumors of the head and neck. Dentomaxillofac. Radiol. 2005, 34, 212-217.
56. Arbab, A. S.; Koizumi, K.; Toyama, K.; Arai, T.; Araki, T. Ion transport systems in the uptake of 99Tcm-tetrofosmin, 99Tcm-MIBI and 201Tl in a tumor cell line. Nucl. Med. Commun. 1997, 18, 235-240.
57. Gungor, F.; Bezircioglu, H.; Guvenc, G.; Tezcan, M.; Yildiz, A.; Uluc, E.; Isisag, A. Correlation of thallium-201 uptake with proliferating cell nuclear antigen in brain tumors. Nucl. Med. Commun. 2000, 21, 803-810.
58. Ishibashi, M.; Fujii, T.; Yamana, H.; Fujimoto, K.; Rikimaru, T.; Hayashi, A.; Kurata, S.; Hayabuchi, N. Relationship between cancer cell proliferation and thallium-201 uptake in lung cancer. Ann. Nucl. Med. 2000, 14, 255-261.
59. Kier, A. B. Plasma membrane properties of cultured local LM cell tumors and metastases from athymic (nude) mice. Cancer Lett. 1990, 50, 19-30.
60. Haas, R. L.; Valdes-Olmos, R. A.; Hoefnagel, C. A.; Verheij, M.; de Jong, D.; Hart, A. A.; Bartelink, H. Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients. Radiother. Oncol. 2003, 69, 323-328.
61. Liang, J. A.; Kao, C. H.; Chen, S. W.; Yang, S. N.; Sun, S. S. The role of thallium-201 whole body scan with pelvic SPECT in patients with uterine cervical cancer treated by radiation therapy: a preliminary report. Ann. Nucl. Med. 2003, 17, 613-617.
62. Vos, M. J.; Hoekstra, O. S.; Barkhof, F.; Berkhof, J.; Heimans, J. J.; van Groeningen, C. J.; Vandertop, W. P.; Slotman, B. J.; Postma, T. J. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J. Clin. Oncol. 2003, 21, 3559-3565. [Epub 2003 Aug 11].
63. Denoyer, D.; Perek, N.; Le Jeune, N.; Frere, D.; Dubois, F. Evidence that 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumor cell lines. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 77-84. [Epub 2003 Oct 14].
64. Kavanaugh, M. P.; Kabat, D. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int. 1996, 49, 959-963.
65. Uckert, W.; Willimsky, G.; Pedersen, F. S.; Blankenstein, T.; Pedersen, L. RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum. Gene Ther. 1998, 9, 2619-2627.
66. Miller, D. G.; Miller, A. D. A family of retroviruses that utilize related phosphate transporters for cell entry. J. Virol. 1994, 68, 8270-8276.
67. Johann, S. V.; Gibbons, J. J.; O'Hara, B. GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J. Virol. 1992, 66, 1635-1640.
68. Werner, A.; Dehmelt, L.; Nalbant, P. Na+-dependent phosphate cotransporters: the NaPi protein families. J. Exp. Biol. 1998, 201, 3135-3142.
69. Horiuchi, K.; Saji, H.; Yokoyama, A. pH sensitive properties of Tc(V)-DMS: analytical and in vitro cellular studies. Nucl. Med. Biol. 1998, 25, 689-695.
70. Horiuchi, K.; Saji, H.; Yokoyama, A. Tc(V)-DMS tumor localization mechanism: a pH-sensitive Tc(V)-DMS-enhanced target/nontarget ratio by glucose-mediated acidosis. Nucl. Med. Biol. 1998, 25, 549-555.
71. Denoyer, D.; Perek, N.; Le Jeune, N.; Cornillon, J.; Dubois, F. Correlation between(99m)Tc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines. Eur. J. Nucl. Med. Mol. Imaging 2005, 23, 23.
72. Papantoniou, V.; Tsiouris, S.; Mainta, E.; Valotassiou, V.; Souvatzoglou, M.; Sotiropoulou, M.; Nakopoulou, L.; Lazaris, D.; Louvrou, A.; Melissinou, M.; Tzannetaki, A.; Pirmettis, I.; Koutsikos, J.; Zerva, C. Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography. Breast Cancer Res. 2005, 7, R33-R45. [Epub 2004 Nov 8].
73. Denoyer, D.; Perek, N.; Jeune, N. L.; Frere, D.; Sabido, O.; Clotagatide, A.; Dubois, F. In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1421-1427. [Epub 2004 Jun 16].
74. Oruckaptan, H. H.; Senmevsim, O.; Ozcan, O. E.; Ozgen, T. Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg. Neurol. 2000, 53, 211-219.
75. Woollons, A. C.; Hunn, M. K.; Rajapakse, Y. R.; Toomath, R.; Hamilton, D. A.; Conaglen, J. V.; Balakrishnan, V. Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin. Endocrinol. (Oxf.) 2000, 53, 713-717.
76. Colao, A.; Ferone, D.; Lombardi, G.; Lastoria, S. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. Clin. Endocrinol. (Oxf.) 2002, 56, 713-721.
77. Athanasoulis, T.; Koutsikos, J.; Moulopoulos, L. A.; Tsiouris, S.; Dimopoulos, M. A.; Zerva, C. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy. Clin. Nucl. Med. 2003, 28, 631-635.
78. Horiuchi-Suzuki, K.; Konno, A.; Ueda, M.; Fukuda, Y.; Nishio, S.; Hashimoto, K.; Saji, H. Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 388-398. [Epub 2003 Nov 29].
79. Fadok, V. A.; Savill, J. S.; Haslett, C.; Bratton, D. L.; Doherty, D. E.; Campbell, P. A.; Henson, P. M. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J. Immunol. 1992, 149, 4029-4035.
80. Tait, J. F.; Gibson, D. Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch. Biochem. Biophys. 1992, 298, 187-191.
81. Koopman, G.; Reutelingsperger, C. P.; Kuijten, G. A.; Keehnen, R. M.; Pals, S. T.; van Oers, M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994, 84, 1415-1420.
82. Blankenberg, F. G.; Katsikis, P. D.; Tait, J. F.; Davis, R. E.; Naumovski, L.; Ohtsuki, K.; Kopiwoda, S.; Abrams, M. J.; Darkes, M.; Robbins, R. C.; Maecker, H. T.; Strauss, H. W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. USA 1998, 95, 6349-6354.
83. Blankenberg, F. G.; Katsikis, P. D.; Tait, J. F.; Davis, R. E.; Naumovski, L.; Ohtsuki, K.; Kopiwoda, S.; Abrams, M. J.; Strauss, H. W. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J. Nucl. Med. 1999, 40, 184-191.
84. Murakami, Y.; Takamatsu, H.; Taki, J.; Tatsumi, M.; Noda, A.; Ichise, R.; Tait, J. F.; Nishimura, S. 18F-labeled annexin V: a PET tracer for apoptosis imaging. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 469-474. [Epub 2003 Dec 10].
85. Toretsky, J.; Levenson, A.; Weinberg, I. N.; Tait, J. F.; Uren, A.; Mease, R. C. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl. Med. Biol. 2004, 31, 747-752.
86. Zijlstra, S.; Gunawan, J.; Burchert, W. Synthesis and evaluation of a 18F-labeled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl. Radiat. Isot. 2003, 58, 201-207.
87. Collingridge, D. R.; Glaser, M.; Osman, S.; Barthel, H.; Hutchinson, O. C.; Luthra, S. K.; Brady, F.; Bouchier-Hayes, L.; Martin, S. J.; Workman, P.; Price, P.; Aboagye, E. O. In vitro selectivity, in vivo biodistribution and tumor uptake of annexin V radiolabeled with a positron emitting radioisotope. Br. J. Cancer 2003, 89, 1327-1333.
88. Cornelissen, B.; Lahorte, C.; Kersemans, V.; Capriotti, G.; Bonanno, E.; Signore, A.; Van de Wiele, C.; Dierckx, R. A.; Slegers, G. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumor-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. Nucl. Med. Biol. 2005, 32, 233-239.
89. Yang, D. J.; Azhdarinia, A.; Wu, P.; Yu, D. F.; Tansey, W.; Kalimi, S. K.; Kim, E. E.; Podoloff, D. A. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother. Radiopharm. 2001, 16, 73-83.
90. Mochizuki, T.; Kuge, Y.; Zhao, S.; Tsukamoto, E.; Hosokawa, M.; Strauss, H. W.; Blankenberg, F. G.; Tait, J. F.; Tamaki, N. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V. J. Nucl. Med. 2003, 44, 92-97.
91. Belhocine, T.; Steinmetz, N.; Green, A.; Rigo, P. In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann. N. Y. Acad. Sci. 2003, 1010, 525-529.
92. Kuge, Y.; Sato, M.; Zhao, S.; Takei, T.; Nakada, K.; Seki, K. I.; Strauss, H. W.; Blankenberg, F. G.; Tait, J. F.; Tamaki, N. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 2004, 45, 309-312.
93. Chen, C. J.; Chin, J. E.; Ueda, K.; Clark, D. P.; Pastan, I.; Gottesman, M. M.; Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
94. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
95. Ueda, K.; Cardarelli, C.; Gottesman, M. M.; Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 1987, 84, 3004-3008.
96. Homolya, L.; Varadi, A.; Sarkadi, B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003, 17, 103-114.
97. Cole, S. P.; Deeley, R. G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 1998, 20, 931-940.
98. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
99. Piwnica-Worms, D. P.; Kronauge, J. F.; LeFurgey, A.; Backus, M.; Hockett, D.; Ingram, P.; Lieberman, M.; Holman, B. L.; Jones, A. G.; Davison, A. Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn. Reson. Imaging 1994, 12, 641-652.
100. Backus, M.; Piwnica-Worms, D.; Hockett, D.; Kronauge, J.; Lieberman, M.; Ingram, P.; LeFurgey, A. Microprobe analysis of Tc-MIBI in heart cells: calculation of mitochondrial membrane potential. Am. J. Physiol. 1993, 265, C178-187.
101. Piwnica-Worms, D.; Chiu, M. L.; Budding, M.; Kronauge, J. F.; Kramer, R. A.; Croop, J. M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993, 53, 977-984.
102. Hendrikse, N. H.; Franssen, E. J.; van der Graaf, W. T.; Meijer, C.; Piers, D. A.; Vaalburg, W.; de Vries, E. G. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br. J. Cancer 1998, 77, 353-358.
103. Perek, N.; Prevot, N.; Koumanov, F.; Frere, D.; Sabido, O.; Beauchesne, P.; Dubois, F. Involvement of the glutathione Sconjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl. Med. Biol. 2000, 27, 299-307.
104. Perek, N.; Denoyer, D. The multidrug resistance mechanisms and their interactions with the radiopharmaceutical probes used for an in vivo detection. Curr. Drug Metab. 2002, 3, 97-113.
105. Le Jeune, N.; Perek, N.; Denoyer, D.; Dubois, F. Influence of glutathione depletion on plasma membrane cholesterol esterification and on Tc-99m-sestamibi and Tc-99m-tetrofosmin uptakes: a comparative study in sensitive U-87-MG and multidrug-resistant MRP1 human glioma cells. Cancer Biother. Radiopharm. 2004, 19, 411-421.
106. Burak, Z.; Moretti, J. L.; Ersoy, O.; Sanli, U.; Kantar, M.; Tamgac, F.; Basdemir, G. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J. Nucl. Med. 2003, 44, 1394-1401.
107. Zhang, X. M.; Zhang, Z. W.; Wu, H. [Correlation between uptake of 99Tcm-MIBI and expression of multidrug resistant protein in breast cancer]. Zhonghua Zhong Liu Za Zhi 2004, 26, 353-355.
108. Kawata, K.; Kanai, M.; Sasada, T.; Iwata, S.; Yamamoto, N.; Takabayashi, A. Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer. Clin. Cancer Res. 2004, 10, 3788-3793.
109. Cayre, A.; Cachin, F.; Maublant, J.; Mestas, D.; Feillel, V.; Ferriere, J. P.; Kwiaktowski, F.; Chevillard, S.; Finat-Duclos, F.; Verrelle, P.; Penault-Llorca, F. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int. J. Oncol. 2002, 20, 1049-1055.
110. Kao, C. H.; Tsai, S. C.; Wang, J. J.; Ho, Y. J.; Ho, S. T.; Changlai, S. P. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. Br. J. Haematol. 2001, 113, 369-374.
111. Kao, A.; Shiun, S. C.; Hsu, N. Y.; Sun, S. S.; Lee, C. C.; Lin, C. C. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann. Oncol. 2001, 12, 1561-1566.
112. Del Vecchio, S.; Salvatore, M. 99mTc-MIBI in the evaluation of breast cancer biology. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, S88-S96. [Epub 2004 Apr 23].
113. Moretti, J. L.; Hauet, N.; Caglar, M.; Rebillard, O.; Burak, Z. To use MIBI or not to use MIBI? That is the question when assessing tumor cells. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 836-842.
114. Touboul, M.; Gauchez, A. S.; D'Hardemare Adu, M.; Lunardi, J.; Deverre, J. R.; Pernin, C.; Mathieu, J. P.; Vuillez, J. P.; Fagret, D. Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide. Anticancer Res. 2002, 22, 3349-3356.
115. Bai, J.; Yokoyama, K.; Kinuya, S.; Shiba, K.; Matsushita, R.; Nomura, M.; Michigishi, T.; Tonami, N. In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1523-1529. [Epub 2004 Sep 21].
116. Young, S. D.; Marshall, R. S.; Hill, R. P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA 1988, 85, 9533-9537.
117. Hill, R. P. Tumor progression: potential role of unstable genomic changes. Cancer Metastasis Rev. 1990, 9, 137-147.
118. Rofstad, E. K.; Mathiesen, B.; Henriksen, K.; Kindem, K.; Galappathi, K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res. 2005, 65, 2387-2396.
119. Rofstad, E. K.; Rasmussen, H.; Galappathi, K.; Mathiesen, B.; Nilsen, K.; Graff, B. A. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 2002, 62, 1847-1853.
120. Sanna, K.; Rofstad, E. K. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int. J. Cancer 1994, 58, 258-262.
121. Sakata, K.; Kwok, T. T.; Murphy, B. J.; Laderoute, K. R.; Gordon, G. R.; Sutherland, R. M. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br. J. Cancer 1991, 64, 809-814.
122. Comerford, K. M.; Cummins, E. P.; Taylor, C. T. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004, 64, 9057-9061.
123. Arvold, N. D.; Guha, N.; Wang, D.; Matli, M.; Deen, D. F.; Warren, R. S.; Haas-Kogan, D. A. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 207-212.
124. Irie, N.; Matsuo, T.; Nagata, I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol. 2004, 21, 1-6.
125. Rajendran, J. G.; Wilson, D. C.; Conrad, E. U.; Peterson, L. M.; Bruckner, J. D.; Rasey, J. S.; Chin, L. K.; Hofstrand, P. D.; Grierson, J. R.; Eary, J. F.; Krohn, K. A. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 695-704. [Epub 2003 Mar 11].
126. Kallinowski, F.; Zander, R.; Hoeckel, M.; Vaupel, P. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int. J. Radiat. Oncol. Biol. Phys. 1990, 19, 953-961.
127. Kavanagh, M. C.; Sun, A.; Hu, Q.; Hill, R. P. Comparing techniques of measuring tumor hypoxia in different murine tumors: Eppendorf pO2 Histograph, [3H]misonidazole binding and paired survival assay. Radiat. Res. 1996, 145, 491-500.
128. Chapman, J. D.; Baer, K.; Lee, J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res. 1983, 43, 1523-1528.
129. Ballinger, J. R.; Kee, J. W.; Rauth, A. M. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J. Nucl. Med. 1996, 37, 1023-1031.
130. Biskupiak, J. E.; Krohn, K. A. Second generation hypoxia imaging agents. J. Nucl. Med. 1993, 34, 411-413.
131. Casciari, J. J.; Graham, M. M.; Rasey, J. S. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med. Phys. 1995, 22, 1127-1139.
132. Koh, W. J.; Bergman, K. S.; Rasey, J. S.; Peterson, L. M.; Evans, M. L.; Graham, M. M.; Grierson, J. R.; Lindsley, K. L.; Lewellen, T. K.; Krohn, K. A.; Griffin, T. W. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33, 391-398.
133. Rasey, J. S.; Koh, W. J.; Evans, M. L.; Peterson, L. M.; Lewellen, T. K.; Graham, M. M.; Krohn, K. A. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36, 417-428.
134. Yeh, S. H.; Liu, R. S.; Wu, L. C.; Yang, D. J.; Yen, S. H.; Chang, C. W.; Yu, T. W.; Chou, K. L.; Chen, K. Y. Fluorine-18 fluoromisonidazole tumor to
135. Valk, P. E.; Mathis, C. A.; Prados, M. D.; Gilbert, J. C.; Budinger, T. F. Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole. J. Nucl. Med. 1992, 33, 2133-2137.
136. Foo, S. S.; Abbott, D. F.; Lawrentschuk, N.; Scott, A. M. Functional imaging of intratumoral hypoxia. Mol. Imaging Biol. 2004, 6, 291-305.
137. Tochon-Danguy, H. J.; Sachinidis, J. I.; Chan, F.; Chan, J. G.; Hall, C.; Cher, L.; Stylli, S.; Hill, J.; Kaye, A.; Scott, A. M. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl. Med. Biol. 2002, 29, 191-197.
138. Barthel, H.; Wilson, H.; Collingridge, D. R.; Brown, G.; Osman, S.; Luthra, S. K.; Brady, F.; Workman, P.; Price, P. M.; Aboagye, E. O. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumor hypoxia with positron emission tomography. Br. J. Cancer 2004, 90, 2232-2242.
139. Sorger, D.; Patt, M.; Kumar, P.; Wiebe, L. I.; Barthel, H.; Seese, A.; Dannenberg, C.; Tannapfel, A.; Kluge, R.; Sabri, O. [18F] Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol. 2003, 30, 317-326.
140. Dehdashti, F.; Mintun, M. A.; Lewis, J. S.; Bradley, J.; Govindan, R.; Laforest, R.; Welch, M. J.; Siegel, B. A. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 844-850. [Epub 2003 Apr 12].
141. Laforest, R.; Dehdashti, F.; Lewis, J. S.; Schwarz, S. W. Dosimetry of (60/61/62/64)Cu-ATSM: a hypoxia imaging agent for PET. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 764-770. [Epub 2005 Mar 23].
142. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29, 15-18.
143. Haubner, R. H.; Wester, H. J.; Weber, W. A.; Schwaiger, M. Radiotracer-based strategies to image angiogenesis. Q. J. Nucl. Med. 2003, 47, 189-199.
144. Iwata, H.; Kobayashi, S.; Iwase, H.; Masaoka, A.; Fujimoto, N.; Okada, Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn. J. Cancer Res. 1996, 87, 602-611.
145. Himelstein, B. P.; Muschel, R. J. Induction of matrix metalloproteinase 9 expression in breast carcinoma cells by a soluble factor from fibroblasts. Clin. Exp. Metastasi 1996, 14, 197-208.
146. Himelstein, B. P.; Asada, N.; Carlton, M. R.; Collins, M. H. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med. Pediatr. Oncol. 1998, 31, 471-474.
147. Nguyen, M.; Arkell, J.; Jackson, C. J. Human endothelial gelatinases and angiogenesis. Int. J. Biochem. Cell. Biol. 2001, 33, 960-970.
148. Stupack, D. G.; Cheresh, D. A. Integrins and angiogenesis. Curr. Top. Dev. Biol. 2004, 64, 207-238.
149. Eliceiri, B. P.; Klemke, R.; Stromblad, S.; Cheresh, D. A. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 1998, 140, 1255-1263.
150. Van De Wiele, C.; Oltenfreiter, R.; De Winter, O.; Signore, A.; Slegers, G.; Dierckx, R. A. Tumor angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 699-709. [Epub 2002 Mar 22].
151. Zheng, Q. H.; Fei, X.; Liu, X.; Wang, J. Q.; Stone, K. L.; Martinez, T. D.; Gay, D. J.; Baity, W. L.; Miller, K. D.; Sledge, G. W.; Hutchins, G. D. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4′-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4′-[11C]methoxyphenyl)sulfonyl]benzylamino]- 3-methylbut anamide. Nucl. Med. Biol. 2004, 31, 77-85.
152. Zheng, Q. H.; Fei, X.; DeGrado, T. R.; Wang, J. Q.; Stone, K. L.; Martinez, T. D.; Gay, D. J.; Baity, W. L.; Mock, B. H.; Glick-Wilson, B. E.; Sullivan, M. L.; Miller, K. D.; Sledge, G. W.; Hutchins, G. D. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3- methyl-butyric acid [11C]methyl ester. Nucl. Med. Biol. 2003, 30, 753-760.
153. Furumoto, S.; Takashima, K.; Kubota, K.; Ido, T.; Iwata, R.; Fukuda, H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl. Med. Biol. 2003, 30, 119-125.
154. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K. F.; Goebel, M.; Hein, R.; Wester, H. J.; Kessler, H.; Schwaiger, M. Noninvasive Visualization of the Activated alphavbeta3 Integrin in Cancer Patients by Positron Emission Tomography and [(18)F]Galacto-RGD. PLoS. Med. 2005, 2, e70. [Epub 2005 Mar 29].
155. Chen, X.; Park, R.; Hou, Y.; Khankaldyyan, V.; Gonzales-Gomez, I.; Tohme, M.; Bading, J. R.; Laug, W. E.; Conti, P. S. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1081-1089. [Epub 2004 Apr 29].